Rapport Therapeutics Q3 net loss widens to $40.2 million from $26.9 million
Rapport Therapeutics reported a third-quarter 2026 net loss of $40.2 million, or $0.84 per share, compared with $26.9 million, or $0.71 per share, a year earlier, as research and development expense rose to $34.3 million. The company ended the quarter with $395.0 million in cash, cash equivalents and short-term investments and says its October and November 2026 financings, together with the September 30 balance, fund operations through the end of 2029. For shareholders, the larger loss sits alongside positive Phase 2 topline results for RAP-219 in bipolar mania, reported October 20, 2026.
Key points
- Net loss was $40.2 million for the third quarter of 2026, versus $26.9 million a year earlier; loss per share was $0.84 versus $0.71.
- R&D expense was $34.3 million versus $22.3 million, mainly from RAP-219 clinical development, including the Phase 3 FOS program.
- Cash and short-term investments were $395.0 million at September 30, 2026, down from $436.1 million at June 30, 2026.
- October 2026 offerings had aggregate net proceeds of approximately $410.7 million, and the company expects cash runway through the end of 2029.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.